Ongoing Agreement With Eli Lilly Leads to Discovery of Several New Small Molecule Drugs
$RGBP - Regen BioPharma, Inc. (OTCQBRGBP & RGBPP)
Summary:
- Eli Lilly Agreement
- Milestones Surpassed
- Developing New Small Molecule Drugs
- Cancer
- Lupus
The compounds, thousands upon thousands Regen has tested are Provided by Eli Lilly and Co. ( LLY ) via a Collaborative Agreement that States - Eli Lilly has the Right to License or Purchase Any/All Developed Compounds and New Drugs.
Recently Regen announced Two New Milestones that have led to the Discovery of Several New Small Molecule Drugs that have potential Cancer-Killing effects and Proven success treating Lupus.
Cancer Treatment
They Have Identified a Series of Small Molecule Drugs that Inhibit NR2F6 & also Activate Human Immune Cells ex-vivo.
Evidence has been provided by studies suggesting the new drugs Repress the Body's Immune Response Against Tumors and activate T-Cells that have potential Cancer-Killing Effects.
While Preliminary these Results are Extremely Encouraging. The Agonists are Behaving as Regen Hoped & Expected They Would. These are very exciting times at Regen as the make major leaps now in progress with their program for Cancer treatment.
Autoimmune Therapies
Regen also reported success with their Small Molecule Program and Drugs that inhibit NR2F6 and the treatment of Autoimmune Diseases recently.
Their screening process demonstrated that they have identified the NR2F6 nuclear receptor as a potential, very important immune cell inhibitor (an immune checkpoint). This is critical in developing therapies for treating autoimmune diseases.
These novel chemical compounds have shown success and the potential for treating autoimmune diseases such as Lupus. Regen's Lead Drug Candidate, RG-NAE005 was tested for the maximum dosage and showed no signs of toxicity, or cytotoxicity. This exhibited as a single dose of 2,000 mg/kg and repeated doses of 400 mg/kg.
This is very exciting, as it indicates that the drug will likely be safe in animals as they move forward and begin the efficacy phase of trials.
We think RGBP is a Long Play with Short Term Gain Potential. The Support and Volume has increased and it has shown the potential to bounce up. Recently over 100%. It has retraced giving back all that it gained. Profit taking and more than likely the maturation of Debt Equity financing. Could be an opportunity at this level for new investors, or cost averaging for existent shareholders.
Keep in mind Eli Lilly reserves the right to license and or purchase any compounds developed, and/or new drugs. Regen could be an attractive merge-buyout target at some point.
You Will Find All of the News-Press Releases-Filings & Supporting Information at these Sites:
https://www.regenbiopharmainc.com
https://www.otcmarkets.com/stock/RGBP/overview
https://finance.yahoo.com/quote/RGBP?ltr=1
You can also visit our site for daily updates on ( OTCQB:RGBP - OTCQB:RGBPP )
https://www.smallcapsolutions.com
Robert E. Kreh – Principal
Small Cap Solutions, LLC
robkreh@smallcapsolutions.com
(443) 567-2609
https://www.smallcapsolutions.com
( OTCQB:RGBP ) Disclaimer: You are receiving this because you have requested the information contained in this email, and/or have expressed an interest recently, or in the past to be included in such emails. And/or have requested information/news/updates for Regen BioPharma, Inc. This profile has been compiled by Small Cap Solutions, LLC based on information from the company believed to be true/factual. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at . Small Cap Solutions, LLC has received payment in cash from Value Quest, Inc. for investor relations services rendered for Regen BioPharma, Inc. . Additional inquiries are available by email to or in writing to Small Cap Solutions, LLC 303 Joppa Crossing Ct (Suite #1) Joppa, Md. 21085 This is not a solicitation to buy or sell securities. To "unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile() are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at and/or Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered.
Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker( S )/Broker Dealer with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
